232 related articles for article (PubMed ID: 29650006)
1. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.
Calzetta L; Matera MG; Facciolo F; Cazzola M; Rogliani P
Respir Res; 2018 Apr; 19(1):65. PubMed ID: 29650006
[TBL] [Abstract][Full Text] [Related]
2. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.
Rogliani P; Matera MG; Facciolo F; Page C; Cazzola M; Calzetta L
Br J Pharmacol; 2020 Mar; 177(5):1150-1163. PubMed ID: 31660611
[TBL] [Abstract][Full Text] [Related]
3. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study.
Rogliani P; Ora J; Girolami A; Rossi I; de Guido I; Facciolo F; Cazzola M; Calzetta L
Pulm Pharmacol Ther; 2021 Aug; 69():102050. PubMed ID: 34129945
[TBL] [Abstract][Full Text] [Related]
4. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
Crisafulli E; Zanini A; Pisi G; Pignatti P; Poli G; Scuri M; Chetta A
Expert Rev Respir Med; 2016; 10(5):481-90. PubMed ID: 26938578
[TBL] [Abstract][Full Text] [Related]
5. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
Papi A; Virchow JC; Singh D; Kots M; Vele A; Georges G; Canonica GW
J Allergy Clin Immunol; 2021 Jul; 148(1):262-265.e2. PubMed ID: 33485959
[TBL] [Abstract][Full Text] [Related]
6. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
[TBL] [Abstract][Full Text] [Related]
7. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rogliani P; Facciolo F; Gavaldà A; Matera MG
Eur J Pharmacol; 2014 Dec; 745():135-43. PubMed ID: 25446566
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I
Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292
[TBL] [Abstract][Full Text] [Related]
10. Interaction between corticosteroids and muscarinic antagonists in human airways.
Cazzola M; Calzetta L; Rogliani P; Puxeddu E; Facciolo F; Matera MG
Pulm Pharmacol Ther; 2016 Feb; 36():1-9. PubMed ID: 26656790
[TBL] [Abstract][Full Text] [Related]
11. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
[TBL] [Abstract][Full Text] [Related]
12. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
13. High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
Corradi M; Spinola M; Petruzzelli S; Kuna P
Ther Adv Respir Dis; 2016 Oct; 10(5):492-502. PubMed ID: 27340255
[TBL] [Abstract][Full Text] [Related]
14. The effect of beclometasone dipropionate/formoterol extra-fine fixed combination on the peripheral airway inflammation in controlled asthma.
Bulac S; Cimrin A; Ellidokuz H
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):82-7. PubMed ID: 25050594
[TBL] [Abstract][Full Text] [Related]
15. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
[TBL] [Abstract][Full Text] [Related]
16. Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics.
Popov TA; Petrova D; Kralimarkova TZ; Ivanov Y; Popova T; Peneva M; Odzhakova T; Ilieva Y; Yakovliev P; Lazarova T; Georgiev O; Hodzhev V; Hodzheva E; Staevska MT; Dimitrov VD
Pulm Pharmacol Ther; 2013 Dec; 26(6):624-9. PubMed ID: 23769863
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.
Calzetta L; Rogliani P; Mattei M; Alfonsi P; Cito G; Pistocchini E; Cazzola M; Matera MG
COPD; 2017 Oct; 14(5):526-532. PubMed ID: 28745522
[TBL] [Abstract][Full Text] [Related]
18. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
Rogliani P; Ritondo BL; Facciolo F; Matera MG; Nikolaev I; Calzetta L
Pharmacol Res; 2021 Oct; 172():105801. PubMed ID: 34363950
[TBL] [Abstract][Full Text] [Related]
19. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma.
Scichilone N; Battaglia S; Sorino C; Paglino G; Martino L; Paternò A; Santagata R; Spatafora M; Nicolini G; Bellia V
Allergy; 2010 Jul; 65(7):897-902. PubMed ID: 20121764
[TBL] [Abstract][Full Text] [Related]
20. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
